Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS Treatment
FDA approves two fixed-dose combination drug products for HIV-1 infection
September 5th, 2004
The U.S. Food and Drug Administration (FDA) announced the approvals of Epzicom (abacavir/lamivudine) and Truvada (tenofovir disoproxil/emtricitabine), two fixed-dose combination treatments for HIV-1 infection. Control of HIV/AIDS generally requires simultaneous use of three or more drugs from different classes. Combination products bring together different HIV/AIDS drugs in a single medication or co-package and help make treatment regimens less complicated for patients to follow. "We gained important scientific knowledge during the development of these products that will be especially useful in our efforts to speed the availability of safe and...
Source: Medical Letter on the CDC & FDA (2004-09-05)
|
